Teva launches generic version of Letairis.
Teva Pharmaceutical Industries (TEVA) announced the launch of a generic version of Letairis Tablets, 5 mg and 10 mg, in the U.S. Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to improve exercise ability and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. For all female patients, ambrisentan tablets are only available through a restricted program called the Ambrisentan Risk Evaluation & Mitigation Strategy due to the risk of fetal harm. Letairis has annual sales of nearly $247 million in the U.S., according to IQVIA (IQV) data as of February 2019.
|Printer friendly Cite/link Email Feedback|
|Date:||May 1, 2019|
|Previous Article:||Powell: analysts don't see a strong case for a rate move either way.|
|Next Article:||Treasury Action: markets have whipsaw as Powell stressed the transitory nature.|